Tivic Health Systems (TIVC)
NASDAQ:TIVC
Want to see TIVC full AI Analyst Report?
TIVC Stock Chart & Stats
$1.38
>-$0.01(-2.18%)
At close: 4:00 PM EST
$1.38
>-$0.01(-2.18%)
Day’s Range― - ―
52-Week Range$0.72 - $7.74
Previous CloseN/A
Volume226.20K
Average Volume (3M)99.84K
Market Cap
$3.34M
Enterprise Value-$4.96M
Total Cash (Recent Filing)$12.64M
Total Debt (Recent Filing)$6.45M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,877,926
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)1.09
P/FCF Ratio-0.05
Enterprise Value/Market Cap-1.48
Enterprise Value/Revenue-12.97
Enterprise Value/Gross Profit-154.88
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Pivot To Biopharma (Entolimod)Shifting from consumer neuromodulation to Entolimod-focused biopharma materially expands addressable markets (military ARS, oncology supportive care). This pivot targets higher-margin, reimbursable opportunities and opens avenues for non-dilutive government contracts and grants, improving long-term commercial opportunity.
Vertical Integration Via Velocity Bioworks CDMOOwning manufacturing (Velocity Bioworks) reduces dependency on external contract manufacturers, shortens timelines, and lowers cost per batch for biologics. The CDMO can also pursue third-party clients, diversifying revenue and enhancing gross-margin potential over the medium term.
Stronger Liquidity And Financing OptionsA larger cash position, convertible financing, and a flexible $50M equity facility materially extend runway to fund clinical and manufacturing builds. These funding sources reduce immediate insolvency risk and enable execution of regulatory and development milestones while the company scales its biopharma operations.
Bears Say
Declining Revenue And Poor ProfitabilityMulti-year revenue contraction and deeply negative operating margins show limited product-market traction in legacy businesses and weak internal profitability. Persistent losses reduce internal funding capacity for R&D and manufacturing, increasing reliance on external capital and amplifying execution risk during the biopharma transition.
Sustained Negative Cash FlowConsistent negative operating and free cash flow—even if improving in magnitude—indicates the business cannot self-fund development and operations. Volatile FCF and ongoing cash burn raise the probability of dilutive financings or covenant pressure, constraining strategic flexibility over the next several quarters.
Listing And Governance OverhangA Nasdaq minimum bid-price notice and cancelled shareholder meeting signal weak investor engagement and potential delisting risk. Combined with earlier capital erosion, these governance and liquidity pressures can increase cost of capital, reduce market access for follow-on funding, and impair shareholder liquidity.
Tivic Health Systems News
TIVC FAQ
What was Tivic Health Systems’s price range in the past 12 months?
Tivic Health Systems lowest stock price was $0.72 and its highest was $7.74 in the past 12 months.
What is Tivic Health Systems’s market cap?
Tivic Health Systems’s market cap is $3.34M.
When is Tivic Health Systems’s upcoming earnings report date?
Tivic Health Systems’s upcoming earnings report date is May 18, 2026 which is in 24 days.
How were Tivic Health Systems’s earnings last quarter?
Currently, no data Available
Is Tivic Health Systems overvalued?
According to Wall Street analysts Tivic Health Systems’s price is currently Overvalued.
Does Tivic Health Systems pay dividends?
Tivic Health Systems does not currently pay dividends.
What is Tivic Health Systems’s EPS estimate?
Tivic Health Systems’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tivic Health Systems have?
Tivic Health Systems has 2,877,926 shares outstanding.
What happened to Tivic Health Systems’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tivic Health Systems?
Currently, no hedge funds are holding shares in TIVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tivic Health Systems
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
TIVC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.View all TIVC earnings summariesTechnical Analysis
Ownership Overview
1.66% Insiders
0.28% Mutual Funds
7.65% Other Institutional Investors
90.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---